Home > Healthcare IT > Global Tuberculosis Drugs Market Size, Growth, Report to 2026
Straits Research

Tuberculosis (TB) Drugs Market

Tuberculosis (TB) Drugs Market: Information by Disease Type (Active TB, Latent TB), Therapy (First-Line, Second-Line), and Region — Forecast till 2026

Table of Content Download Sample

Market Overview

The global tuberculosis drugs market size was valued at around USD 895.5 million in 2017 and is anticipated to exhibit a CAGR of 6.3% during the forecast period. 

Tuberculosis is caused by the Mycobacterium tuberculosis bacterium. It spreads when a person with active TB coughs or sneezes and the bacteria come in contact with a healthy person. A weakened immune system is the key cause of tuberculosis prevalence. According to the Central for Diseases Control and Prevention, around one-fourth of the world's population is infected with TB. Further, TB is a vastly prevalent disease among people affected by HIV. According to the Centers for Disease Control and Prevention, in 2017, 10 million people suffered from TB around the globe. Treatments such as biological agents or chemotherapy that weaken the immune system further increases the chances of contracting tuberculosis.

Market Snapshot

market snapshot
Base Year
: 2017
Study Period
: 2016-2026
: 6.3 %
Fastest Growing Market
: Asia Pacific
Largest Market
: North America
Market Size
: USD 895.5 million in 2017 
Get more information on this report Download Sample Report

Segmental Analysis

The global tuberculosis drugs market can be segmented by disease type and therapy.

On the basis of disease type, the tuberculosis drugs market can be segmented into active TB and latent TB. The active TB segment is expected to dominate the market, due to the increasing incidences of DS and MDR TB cases. Based on therapy, the market can be segmented into first-line therapy and second-line therapy. Among the two, the second line therapy segment is expected to lead the market, owing to rising national surveillance efforts and global initiatives by WHO and Global Drug Facility (GDF).

Regional Analysis

Geographically, the tuberculosis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (LAMEA).

North America is projected to account for the largest share of the global tuberculosis drugs market during the forecast period, 2019–2026. Increasing prevalence of chronic diseases such as HIV diseases, which weaken the immune system is a key factor providing an impetus to the growth of the tuberculosis drugs market. According to the National Aids Control Organisation (NACO), in 2015, around 1.1 million people suffered from HIV.

Europe is expected to witness significant market growth during the forecast period, owing to the region’s sizable geriatric population. For instance, according to the U.K. Government, in 2017, around 579,776 people were older than 90 years.

Asia-Pacific is pegged to be the fastest growing market during the forecast period according to WHO, South-East Asia Region have the highest population around 45% of total population suffering from tuberculosis. Apart from that 82% of deaths reported among HIV negative people in  South-East Asia Region in 2016. This increasing number of tuberculosis number in Asia-Pacific drives the tuberculosis drugs market.

The LAMEA region is expected to witness substantial market growth during the forecast period, owing to the increasing prevalence of tuberculosis and high disposable income in the Middle East.

Tuberculosis (TB) Drugs Market Regional Analysis
Regional Growth Insights Download Free Sample

Top Key Players of Tuberculosis (TB) Drugs Market

A list of key tuberculosis drugs market suppliers

  1. Sigma Pharmaceutical Pty Limited
  2. Aventis Pharmaceuticals Limited
  3. Novartis AG
  4. Sanofi Aventis U.S LLC
  5. Hoffmann-La Roche Ltd
  6. Akorn
  7. Incorporated
  8. Bayer Health care.

Report Scope

Report Metric Details
CAGR 6.3%
Forecast Period 2023-2031
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered
  1. By Disease Type
    1. Active TB
    2. Latent TB
  2. By Therapy
    1. First-Line Therapy
    2. Second-Line Therapy.
Geographies Covered
  • North America
  • Europe
  • APAC
  • Middle East and Africa

Recent Developments

In September 2018, QIAGEN N.V. and DiaSorin in collaboration launched automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test which is developed based on immunodiagnostic instruments from DiaSorin. Through this product launch, the company had expanded its product portfolio and Tuberculosis business in Europe

Tuberculosis (TB) Drugs Market Segmentations

By Disease Type

  • Active TB
  • Latent TB

By Therapy

  • First-Line Therapy
  • Second-Line Therapy.

By Regions

  • North America
  • Europe
  • APAC
  • Middle East and Africa

Frequently Asked Questions (FAQs)

Price Starts From
USD 995

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Report Snapshot
Looking For Custom Report ?
Check Our License Options :
Free Sample Report

"Find new revenue generation opportunities"

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers